|
1
|
Heyn H and Esteller M: DNA methylation
profiling in the clinic: Applications and challenges. Nat Rev
Genet. 13:679–692. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hao X, Luo H, Krawczyk M, Wei W, Wang W,
Wang J, Flagg K, Hou J, Zhang H, Yi S, et al: DNA methylation
markers for diagnosis and prognosis of common cancers. Proc Natl
Acad Sci USA. 114:7414–7419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strmsek Z and Kunej T: MicroRNA silencing
by DNA methylation in human cancer: A literature analysis.
Non-Coding RNA. 1:44–52. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suzuki H, Maruyama R, Yamamoto E and Kai
M: DNA methylation and microRNA dysregulation in cancer. Mol Oncol.
6:567–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira
M, Matsumoto H and Horiguchi J: Recent trends in microRNA research
into breast cancer with particular focus on the associations
between microRNAs and intrinsic subtypes. J Hum Genet. 62:15–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang X, Tang J, Liu X, Zeng L, Cheng C,
Luo Y, Li L, Qin SL, Sang Y, Deng LM and Lv XB: Downregulation of
miR-129-2 by promoter hypermethylation regulates breast cancer cell
proliferation and apoptosis. Oncol Rep. 35:2963–2969. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Q, Li H, Zhao X, Wang B, Zhang L, Zhang
C and Zhang F: DNA methylation mediated downregulation of miR-449c
controls osteosarcoma cell cycle progression by directly targeting
oncogene c-Myc. Int J Biol Sci. 13:1038–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He DX, Gu F, Gao F, Hao JJ, Gong D, Gu XT,
Mao AQ, Jin J, Fu L and Ma X: Genome-wide profiles of methylation,
microRNAs, and gene expression in chemoresistant breast cancer. Sci
Rep. 6:247062016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su Y, Fang H and Jiang F: Integrating DNA
methylation and microRNA biomarkers in sputum for lung cancer
detection. Clin Epigenetics. 8:1092016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu J, Zheng Z, Wang J, Sun J, Wang P,
Cheng X, Fu L, Zhang L, Wang Z and Li Z: Different miRNA expression
profiles between human breast cancer tumors and serum. Front Genet.
5:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Agostini M and Knight RA: miR-34: From
bench to bedside. Oncotarget. 5:872–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adams BD, Wali VB, Cheng CJ, Inukai S,
Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, et
al: miR-34a silences c-SRC to attenuate tumor growth in
triple-negative breast cancer. Cancer Res. 76:927–939. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cortez MA, Ivan C, Valdecanas D, Wang X,
Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al:
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108:pii:
djv303. 2015.PubMed/NCBI
|
|
14
|
Stahlhut C and Slack FJ: Combinatorial
action of microRNAs let-7 and miR-34 effectively synergizes with
erlotinib to suppress non-small cell lung cancer cell
proliferation. Cell Cycle. 14:2171–2180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Corney DC, Flesken-Nikitin A, Godwin AK,
Wang W and Nikitin AY: MicroRNA-34b and microRNA-34c are targets of
p53 and cooperate in control of cell proliferation and
adhesion-independent growth. Cancer Res. 67:8433–8438. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daugaard I, Knudsen A, Kjeldsen TE, Hager
H and Hansen LL: The association between miR-34 dysregulation and
distant metastases formation in lung adenocarcinoma. Exp Mol
Pathol. 102:484–491. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng Z, Chen X, Zhu D, Luo Z and Yang M:
Low expression of circulating MicroRNA-34c is associated with poor
prognosis in triple-negative breast cancer. Yonsei Med J.
58:697–702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Strmsek Z and Kunej T: Data integration of
104 studies related with microRNA epigenetics revealed that miR-34
gene family is silenced by DNA methylation in the highest number of
cancer types. Discov J. 2:e182014. View Article : Google Scholar
|
|
19
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogt M, Munding J, Grüner M, Liffers ST,
Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A and Hermeking H:
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG
methylation in colorectal, pancreatic, mammary, ovarian,
urothelial, and renal cell carcinomas and soft tissue sarcomas.
Virchows Arch. 458:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuengaf LM, Rossic S, Nicolosoc
MS, Fallerg WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siemens H, Neumann J, Jackstadt R,
Mansmann U, Horst D, Kirchner T and Hermeking H: Detection of
miR-34a promoter methylation in combination with elevated
expression of c-Met and β-catenin predicts distant metastasis of
colon cancer. Clin Cancer Res. 19:710–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Chen Z, Gao Z, Li N, Li B, Tan F,
Tan X, Lu N, Sun Y, Sun J, et al: DNA hypermethylation of
microRNA-34b/c has prognostic value for stage I non-small cell lung
cancer. Cancer Biol Ther. 11:490–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casadio V, Molinari C, Calistri D, Tebaldi
M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R,
Amadori D and Zoli W: DNA methylation profiles as predictors of
recurrence in non muscle invasive bladder cancer: An MS-MLPA
approach. J Exp Clin Cancer Res. 32:942013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Troester MA, Hoadley KA, D'Arcy M,
Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen
H, Wilkerson MD, et al: DNA defects, epigenetics, and gene
expression in cancer-adjacent breast: A study from The Cancer
Genome Atlas. NPJ Breast Cancer. 2:160072016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao B, Feng L, Lu D, Liu Y, Liu Y, Guo S,
Han N, Liu X, Mao Y, He J, et al: Prognostic value of molecular
events from negative surgical margin of non-small-cell lung cancer.
Oncotarget. 8:53642–53653. 2016.PubMed/NCBI
|
|
27
|
Yan PS, Venkataramu C, Ibrahim A, Liu JC,
Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, et al:
Mapping geographic zones of cancer risk with epigenetic biomarkers
in normal breast tissue. Clin Cancer Res. 12:6626–6636. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Teschendorff AE, Gao Y, Jones A, Ruebner
M, Beckmann MW, Wachter DL, Fasching PA and Widschwendter M: DNA
methylation outliers in normal breast tissue identify field defects
that are enriched in cancer. Nat Commun. 7:104782016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson KC, Koestler DC, Fleischer T, Chen
P, Jenson EG, Marotti JD, Onega T, Kristensen VN and Christensen
BC: DNA methylation in ductal carcinoma in situ related with future
development of invasive breast cancer. Clin Epigenetics. 7:752015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schrijver WA, Jiwa LS, van Diest PJ and
Moelans CB: Promoter hypermethylation profiling of distant breast
cancer metastases. Breast Cancer Res Treat. 151:41–55. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu XD, Song YC, Cao PL, Zhang H, Guo Q,
Yan R, Diao DM, Cheng Y and Dang CX: Detection of miR-34a and
miR-34b/c in stool sample as potential screening biomarkers for
noninvasive diagnosis of colorectal cancer. Med Oncol. 31:8942014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suzuki H, Yamamoto E, Nojima M, Kai M,
Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, et al:
Methylation-associated silencing of microRNA-34b/c in gastric
cancer and its involvement in an epigenetic field defect.
Carcinogenesis. 31:2066–2073. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clark SJ, Harrison J, Paul CL and Frommer
M: High sensitivity mapping of methylated cytosines. Nucleic Acids
Res. 22:2990–2997. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lan VT, Ha NT, Uyen NQ, Duong NT, Huong
NT, Thuan TB, Duong PA and To TV: Standardization of the
methylation-specific PCR method for analyzing BRCA1 and ER
methylation. Mol Med Rep. 9:1844–1850. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tarasov V, Jung P, Verdoodt B, Lodygin D,
Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential
regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-Cell translocation gene 4 is associated with
CpG Island methylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beg MS, Brenner AJ, Sachdev J, Borad M,
Kang YK, Stoudemire J, Smith S, Bader AG, Kim S and Hong DS: Phase
I study of MRX34, a liposomal miR-34a mimic, administered twice
weekly in patients with advanced solid tumors. Invest New Drugs.
35:180–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim YH, Lee WK, Lee EB, Son JW, Kim DS and
Park JY: Combined effect of metastasis-related microRNA, miR-34 and
miR-124 family, methylation on prognosis of Non-Small-Cell lung
cancer. Clin Lung Cancer. 18:e13–e20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tan W, Gu J, Huang M, Wu X and Hildebrandt
MA: Epigenetic analysis of microRNA genes in tumors from surgically
resected lung cancer patients and association with survival. Mol
Carcinog. 54 Suppl 1:E45–E51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dakhlallah D, Batte K, Wang Y,
Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright
VP, Nana-Sinkam SP, et al: Epigenetic regulation of miR-17 ~92
contributes to the pathogenesis of pulmonary fibrosis. Am J Respir
Crit Care Med. 187:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Piletič K and Kunej T: MicroRNA epigenetic
signatures in human disease. Arch Toxicol. 90:2405–2419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schmid G, Notaro S, Reimer D, Abdel-Azim
S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin
N, et al: Expression and promotor hypermethylation of miR-34a in
the various histological subtypes of ovarian cancer. BMC Cancer.
16:1022016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cui X, Zhao Z, Liu D, Guo T, Li S, Hu J,
Liu C, Yang L, Cao Y, Jiang J, et al: Inactivation of miR-34a by
aberrant CpG methylation in Kazakh patients with esophageal
carcinoma. J Exp Clin Cancer Res. 33:202014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Samuel N, Wilson G, Lemire M, Said Id B,
Lou Y, Li W, Merino D, Novokmet A, Tran J, Nichols NE, et al:
Genome-wide DNA methylation analysis reveals epigenetic
dysregulation of microRNA-34A in TP53-associated cancer
susceptibility. J Clin Oncol: pii: JCO676940. 2016. View Article : Google Scholar
|
|
47
|
Tanaka N, Toyooka S, Soh J, Kubo T,
Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, et al:
Frequent methylation and oncogenic role of microRNA-34b/c in
small-cell lung cancer. Lung Cancer. 76:32–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kristensen LS and Hansen LL: PCR-based
methods for detecting single-locus DNA methylation biomarkers in
cancer diagnostics, prognostics, and response to treatment. Clin
Chem. 55:1471–1483. 2009. View Article : Google Scholar : PubMed/NCBI
|
